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Background: The β2-adrenoceptor agonist dopexaminemay possess anti-inflammatory
actions which could reduce organ injury during endotoxemia and laparotomy. Related
effects on leucocyte-endothelial adhesion remain unclear.
Methods: Thirty anesthetized Wistar rats underwent laparotomy followed by induction
of endotoxemia with lipopolysaccharide and peptidoglycan (n = 24) or sham (n = 6).
Animals received dopexamine at 0.5 or 1 µg kg−1 min−1 (D0.5 and D1), salbutamol at
0.1 µg kg−1 min−1, or saline vehicle (Sham and Control) for 5 h. Intravital microscopy
was performed in the ileum of the small intestine to assess leucocyteendothelial
adhesion, arteriolar diameter, and functional capillary density. Global hemodynamics and
biochemical indices of renal and hepatic function were also measured.
Results: Endotoxemia was associated with an increase in adherent leucocytes
in post-capillary venules, intestinal arteriolar vasoconstriction as well-reduced arterial
pressure and relative cardiac index, but functional capillary density in the muscularis was
not significantly altered. Dopexamine and salbutamol administration were associatedwith
reduced leucocyte-endothelial adhesion in post-capillary venules compared to control
animals. Arteriolar diameter, arterial pressure and relative cardiac index all remained
similar between treated animals and controls. Functional capillary density was similar
for all groups. Control group creatinine was significantly increased compared to sham
and higher dose dopexamine.
Conclusions: In a rodent model of laparotomy and endotoxemia, β2-agonists were
associated with reduced leucocyte-endothelial adhesion in post-capillary venules. This
effect may explain some of the anti-inflammatory actions of these agents.
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INTRODUCTION
Complications following major gastrointestinal surgery have a
significant impact on both short and long-term survival (1–3).
Inotropic agents may have important effects on outcomes for
this patient group (4). Dopexamine is a dopamine analog with
agonist activity at β2-adrenoceptor and dopaminergic receptors.
This spectrum of activity confers vasodilator actions in addition
to chronotropic and mild inotropic effects (5). Dopexamine
has been used to increase cardiac output and hence tissue
oxygen delivery in several trials of peri-operative haemodynamic
therapy (6, 7). Other cardiovascular effects of dopexamine may
include improved tissue microvascular flow and oxygenation
(8). Various groups have studied the effects of dopexamine in
patients following major gastrointestinal surgery (6, 9), with
promising results, although the findings of a recent large trial
were inconclusive (7).
Investigators have previously demonstrated potent anti-
inflammatory effects of β2-adrenoceptor agonists (10–18), in
particular dopexamine (19–22). However, it is unclear that
β2-adrenoceptor agonism is responsible for the dopexamine-
dependent reduction of leucocyte-endothelial adhesion seen in
several endotoxemia studies (19, 20). The findings of previous
laboratory and clinical investigations suggest dopexamine may
improve tissue microvascular flow and oxygenation (8, 19,
20, 23–26), and it is thought that these effects may account
for much of the potential benefit of inotropic agents in the
critically ill (27). However, in a previous laboratory study from
our group, the haemodynamic actions of dopexamine infusion
appeared to be less important than anti-inflammatory effects,
including decreased plasma cytokine levels, modulation of
neutrophil CD11b surface expression, and decreased pulmonary
neutrophil infiltration (28). We sought to further clarify
how leucocyte-endothelial adhesion under endotoxemia might
relate to the β2-adrenoceptor agonist effects of dopexamine,
and its effects on arterial pressure, cardiac output and
the microcirculation.
We therefore investigated the effects of dopexamine on
leucocyte-endothelial adhesion within the microcirculation. Our
hypothesis was that, in a rodent model of laparotomy and
endotoxemia, dopexamine would decrease leucocyte-endothelial
adhesion in intestinal post-capillary venules, through β2-
adrenoceptor mediated actions. The relative contribution of β2-
adrenoceptor agonism to these effects was assessed by using the
β2 adrenergic agonist salbutamol as a comparator.
MATERIALS AND METHODS
Thirty male Wistar rats (240–340 g) received a standard diet and
water ad libitum before the experiments. All procedures were
performed with institutional approval and in accordance with
the United Kingdom Home Office Guidance on the Operation
of the Animals (Scientific Procedures) Act 1986 under the
project license PPL 70/6526. Anesthesia was induced by intra-
peritoneal injection of thiopental (120mg kg−1) and maintained
with supplementary injections administered according to regular
testing for limb withdrawal to a standard stimulus. Animals were
placed on a warming mat to maintain a core temperature of 37±
0.5◦C. A tracheostomy was performed, following which a short
section of polyethylene tubing (internal diameter, 1.67mm) was
inserted to maintain airway patency and to facilitate spontaneous
respiration. The right carotid artery was cannulated to allow
blood sampling and continuous monitoring of heart rate (HR)
and mean arterial pressure (MAP). The left jugular vein was
cannulated for drug and fluid administration.
A 2 cm midline incision was then made through the
abdominal wall to expose the peritoneum. Following laparotomy,
bowel was evacuated into a moist cotton receptacle. Blunt
dissection was then performed to access the abdominal
vasculature. After isolation from the vena cava, a 1.5mm
ultrasonic aortic transit time flow probe (MA1.5PRB; Transonic
Systems Inc., Ithaca, USA) was placed on the infra-renal aorta
to measure aortic blood flow allowing calculation of relative
stroke volume and relative cardiac index. The bowel was then
replaced in the abdominal cavity, except for a loop of ileum
just proximal to the caecum. The exposed bowel was kept moist
by the application of 0.9% saline drops through a pipette. The
laparotomy incision above and below the exit of the terminal ileal
loop from the abdomen was then closed with 5.0 vicryl to prevent
excessive insensible fluid losses. The animal was maintained on a
warming mat on an intravital microscopy platform and placed
in the right lateral position so the ileal loop fell on to a raised
section of the platform at the level of the laparotomy incision. The
temperature of the raised section was thermostatically controlled
at 37.5◦C to ensure the temperature of the exposed bowel was
similar to the core temperature. This position did not interfere
with the ability of the ultrasonic probes to measure aortic blood
flow. Subsequently the bowel was covered with Saran wrap to
prevent evaporative losses from its surface and maintain bowel
microvascular integrity (29). This was followed by a 5ml kg−1
bolus of normal saline to replace insensible fluid losses and
a 15min stabilization period to allow microvascular flow to
stabilize. A first set of arterial blood samples was then taken
(see below), the volume being replaced with an equal volume
of normal saline. Animals were allowed to stabilize for 15min
before being allocated randomly to one of five groups (sham,
control, D0.5, D1, S).
Endotoxemia was induced over a 10min period in four of
five groups by administering 1ml kg−1 of a solution containing
Escherichia coli lipopolysaccharide 0111:B4 (LPS, 1mg ml−1)
and peptidoglycan (PepG, 0.3mg ml−1) intravenously, the sham
group received 0.9% saline vehicle alone. In all groups this
was followed by an infusion of 0.9% saline at 4.3ml kg−1 h−1
though different doses of dopexamine or salbutamol were added
to the D0.5, D1, and S groups’ infusion fluid. This resulted in
dopexamine infusion rates of 0.5 and 1µg kg−1 min−1 for groups
D0.5 and D1, respectively, and a salbutamol infusion rate of 0.1
µg kg−1 min−1 in group S. This dose of salbutamol was selected
as previous studies conducted in isolated guinea–pig tracheal
preparations showed a 10-fold greater potency of salbutamol
at the β2-adrenoceptor when compared with dopexamine (30).
Intravital microscopy in the intestinal ileum was performed
after 150min, midway through resuscitation. It was not possible
to measure global hemodynamics during this procedure. The
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experiment ended after 5 h of resuscitation when the heart and
lungs were excised.
Analysis of Plasma Lactate, Base Deficit,
and Renal and Hepatic Function
Two hundred microliter of blood was taken at baseline and at
the end of the experiment for measurement of plasma lactate
concentration (Accutrend Lactate; Roche Diagnostics, Basel,
Switzerland) and base deficit (Radiometer ABL77, Copenhagen,
Denmark). A 1ml blood sample was also taken at the end
of the experiment for measurements of urea, creatinine,
alanine aminotransferase, and aspartate aminotransferase by
a commercial veterinary laboratory (IDEXX Laboratories Ltd,
Sussex, UK).
MEASUREMENT OF AORTIC BLOOD
FLOW
A 1.5mm perivascular probe was applied with water-soluble
sonicating gel and sited as described earlier. The probe
was connected to a TS420 monitor (Transonic Systems
Inc., Ithaca, USA), which was connected to a Powerlab/8SP
monitoring system (AD Instruments). This allowed continuous
recording of aortic blood flow and HR, and calculation of
relative stroke volume and relative cardiac output (relative
as infra-renal aortic blood flow is not equivalent to cardiac
output). Aortic blood flow was indexed to body weight to
provide a measure of changes in relative stroke volume index
(SVI) and relative cardiac index (CI). Probe calibration was
performed daily according to the manufacturer’s instructions
before experiments.
Intravital Microscopy (IVM)
Fifteen minutes before the midpoint of fluid resuscitation, 0.2ml
of 0.17 g L−1 rhodamine 6G (Sigma-Aldrich, Gillingham, UK)
was administered intravenously to enhance the visibility of
leucocytes. The animal platform was then transferred to the
stage of an intravital microscope. Fluorescence microscopy was
carried out using an Olympus BX61W1 microscope (Carl Zeiss
Ltd.) connected to an Olympus BXUCB lamp, Uniblitz VCMD1
shutter driver and DG4-700 shutter instrument. Recordings
were captured using Slidebook 5.0 software (Intelligent Imaging
TTL) and saved for later offline analysis. All images were
taken at x40 magnification. Leucocyte rolling and adhesion
(>30 s stationary) was quantified in ileal post-capillary venules:
the course of microvessels of the ileal submucosal layer was
followed from collecting venules (V1) to postcapillary venules
(V3), the latter being selected for analysis. Vessel length and
diameter wasmeasured and recorded. Images were recorded for a
minimum of 40 s. A further 0.2ml of 250mg kg−1 ml−1 of FITC
labeled bovine albumin (Sigma-Aldrich) was then administered
intravenously in order to measure functional capillary density
(FCD) and arteriolar diameters: the course of microvessels of
the ileal submucosal layer was followed from supply arterioles
(A1) to pre-capillary arterioles (A3), the latter being selected for
analysis. Vessel diameter was measured and recorded. Capillaries
were identified in the circular and longitudinal layers of the
ileum and images were recorded for a minimum of 40 s. These
images were later analyzed offline. The platform was then
removed from the microscope stage and observations continued
as before.
Recordings of intravital videos were stored electronically.
These files were later analyzed offline using Slidebook 5.0 Reader
[Intelligent Imaging Innovations (3i)] by an observer blinded
to the experiment groups. Leucocyte adhesion was quantified
and indexed to endothelial surface area (mm2), calculated from
the diameters and lengths of the vessel segments studied and
assuming cylindrical vessel geometry. Firmly adherent leucocytes
were defined as those that did not move or detach from the
endothelial lining within an observation period of 30 s. FCD was
calculated as the total length of perfused capillaries indexed to the
visualized area (mm−1).
Statistical Analysis
Data were presented as Mean (SEM) unless expressed otherwise
and specifically. Kolmogorov-Smirnov normality testing was
performed for all groups. Normally distributed data were tested
using one-way analysis of variance (ANOVA) for comparison
across all groups at a given time point. Post-testing was
performed with Bonferroni’s tests. Occasionally when ANOVA
revealed significant results but post-tests did not indicate which
group was responsible, t-tests (with or withoutWelch’s correction
depending on the variance of data) were performed to gain
additional insight to the data. When data were not normally
distributed in at least one group for any measurement, data were
expressed as median (IQR) and the Kruskal-Wallis test was used
in place of one-way ANOVA with MannWhitney post-tests (and
a Bonferroni correction). Two-tailed paired t-tests were used
to compare hemodynamics at baseline with those at other time
points for animals within the same group. Data were analyzed
with PrismGraph 4.0 (GraphPad Software, San Diego, USA).
Significance was set at p < 0.05.
RESULTS
Baseline characteristics and fluid management are described
in (Table 1 and Supplementary Table 1). There were no
significant differences between groups regarding weight
or volume of fluid received. Animals in the sham group
required a slightly greater dose of thiopental to maintain
anesthesia (Supplementary Table 1). There were no baseline
differences in hemodynamics, base deficit, lactate or
hematocrit. In the sham group, MAP and HR did not change
significantly but CI and SVI increased progressively (Table 1,
Figure 1, Supplementary Table 1, Supplementary Figures 1, 2).
Compared with the sham group and baseline, controls had a
significantly higher HR (p < 0.05) and a significantly lower SVI
and CI at 5 h (Table 1, Figure 1, Supplementary Figures 1, 2).
At this point control group plasma base deficit and lactate were
increased compared with sham animals, the latter significantly
(p < 0.05) (Table 1, Supplementary Figure 3). Compared to
shams, there were more firmly adherent leucocytes (control: 703
± 86 mm−2 vs. sham: 186 ± 68 mm−2; p < 0.001), and fewer
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TABLE 1 | Fluid administered, temporal changes in blood gas and haemodynamic parameters for each group (n = 6 all groups).
Sham Control D 0.5 D1 S
Administered
fluid (ml kg−1)
29.9
(29.2–30.5)
29.4
(29.3–29.5)
29.8
(29.4–30.5)
30.1
(29.4–30.5)
29.8
(29.4–30.4)
Baseline HR (bpm) 378
(357–421)
399
(379–417)
415
(390–420)
379
(356–441)
392
(370–423)
Baseline MAP (mmHg) 120 (7) 111 (3) 114 (5) 108 (3) 110 (6)
End experiment HR (bpm) 371 (8)*** 447 (12) 465 (15) 478 (9) 445 (5)
End experiment MAP (mmHg) 114
(95–133)
93
(69–101)
81
(76–106)
94
(79–106)
78
(70–106)
End experiment lactate
(mmol L−1)
1.7 (0.2)* 3.4 (0.5) 3.1 (0.3) 2.6 (0.4) 3.8 (0.3)
End experiment base
deficit
(mmol L−1)
−0.6 (1.0) 4.5 (1.6) 2.9 (1.5) 3.3 (1.5) 6.0 (1.0)
Mean change in SVI during experiment
(ml kg−1)
0.044 (0.014)* −0.036 (0.008)** −0.050 (0.009)** −0.054 (0.003)*** −0.020 (0.011)
Mean change in CI during experiment
(ml min−1 kg−1)
15.3
(6.2)
−10.5
(3.2)*
−16.1
(4.2)*
−14.4
(2.0)***
3.0
(4.9)
There were no significant differences between groups in baseline hemodynamics or volumes of fluid administered. Over the course of the experiment in shams SVI significantly increased
and CI also tended to increase, though HR and MAP did not change. In contrast HR significantly increased, while SVI and CI significantly decreased in control and dopexamine groups.
MAP was significantly decreased, though this was not a consistent finding. HR also significantly increased in group S and although CI and SVI remained relatively stable MAP decreased
significantly. A significantly lower lactate was seen in shams compared to controls. Data presented as mean (SEM) when all groups normally distributed, otherwise median (IQR) if ≥ 1
group not normally distributed. One-way ANOVA (post hoc Bonferroni’s test, *p < 0.05, **p < 0.01, ***p < 0.001 vs. controls). Paired t-tests of baseline vs. end experiment for mean
changes (*p < 0.05, **p < 0.01, ***p < 0.001).
FIGURE 1 | Relative Stroke Volume Index during 5 h of laparotomy and endotoxemia recorded every 30min. Values not plotted for t180–t210 [animals were
undergoing IVM at this time and aortic flow and HR could not be measured (therefore relative SVI could not be calculated)]. Relative stroke volume index in controls
differed significantly for most of the experiment and until its end when compared to shams. However, no significant differences in relative stroke volume index were
observed between controls and groups treated with dopexamine or salbutamol at any time. The mean change in relative stroke volume index from baseline to end
experiment was also significant in all groups except salbutamol treated animals (also see Table 1). Data presented as mean (SEM). One-way ANOVA at each time
point (Bonferroni’s post-tests, **p < 0.01, ***p < 0.001 vs. controls).
rolling leucocytes in the post-capillary venules of control animals
(Figure 2, Supplementary Figure 4). Intestinal arteriolar
diameters were reduced in control animals [control: 21 ± 2µm
vs. sham: 39 ± 3µm; p < 0.01; Figure 2 (mid)] although FCD
in the muscularis and its component circular and longitudinal
layers did not differ significantly from shams [Figure 2 (right),
Supplementary Figure 4]. Endotoxemia was associated with
acute kidney injury but not liver dysfunction (Figure 3).
Dopexamine infusion had no significant effect on
any haemodynamic parameters when compared to
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FIGURE 2 | (Left) Numbers of adherent leucocytes per square mm of endothelium in ileal post-capillary venules at 2.5 h of laparotomy and endotoxemia (n = 6 all
groups). Numbers of vessels observed per group ranged from 8 to 18. Sham, dopexamine, and salbutamol treated groups demonstrated significantly less adhesion
than controls. Data presented as mean (SEM). One-way ANOVA (Bonferroni’s post-tests, *p < 0.05, **p < 0.01, ***p < 0.001 vs. controls). (Mid) Intestinal arteriolar
diameters of the ileum at 2.5 h of laparotomy and endotoxemia (n = 6 all groups). Numbers of vessels measured per group ranged from 8 to 19. When compared to
shams and unlike controls, ileal arteriolar diameters were not significantly reduced in dopexamine and salbutamol treated groups. Data presented as mean (SEM).
One-way ANOVA (Bonferroni’s post-tests, **p < 0.01 vs. shams). (Right) Intestinal functional capillary density in longitudinal layers of the ileal muscularis at 2.5 h of
laparotomy and endotoxemia (n = 6 all groups). Number of images per group ranged from 16 to 25. Groups were significantly different with respect to longitudinal
FCD at 2.5 h. Data presented as mean (SEM). One-way ANOVA p = 0.024 (no groups positive in post-tests, although p < 0.01 when comparing control and D1
group with unpaired t-test with Welch’s correction).
FIGURE 3 | Plasma urea, creatinine, ALT and AST sampled 5 h after laparotomy and endotoxemia (n = 6 all groups). 5 h of laparotomy and endotoxemia caused
significant acute kidney injury in controls. The degree of injury was significantly less in the D1 group. All data presented as mean (SEM). Plasma urea and creatinine:
One-way ANOVA (Bonferroni’s post-tests, *p < 0.05, **p < 0.01, ***p < 0.001 vs. controls). ALT: One-way ANOVA, p = 0.0246 (no groups positive in post-tests).
controls, except for an increase in heart rate (Table 1,
Figure 1, Supplementary Table 1, Supplementary Figures 1, 2).
Similarly, dopexamine was not associated with any improvement
in plasma lactate or base deficit in endotoxaemic animals
(Table 1, Supplementary Figure 3). The major finding of this
study was that at the mid-point of resuscitation dopexamine
significantly reduced leucocyte adhesion in post-capillary
venules when compared to controls (D0.5: 409 ± 65 mm−2,
p < 0.05 vs. control; D1: 361 ± 66 mm−2, p < 0.01 vs. control)
(Figure 2). Furthermore, dopexamine prevented the reduction
in arteriolar diameter observed in control animals [Figure 2
(mid)]. The effects of dopexamine on FCD were complex. There
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were significant differences between groups in longitudinal
muscle FCD (one-way ANOVA p = 0.024) [Figure 2 (right)],
but post-tests did not show which group was responsible for
this difference. However, isolated t-tests comparing each group
against controls reveal that only the D1 group had a significantly
reduced longitudinal FCD compared to controls (unpaired
t-test with Welch’s correction, p = 0.0034). Dopexamine had
no effect on FCD in the circular layer of the muscularis at any
dose. When comparing total muscularis FCD for all groups,
differences fell outside of the limits of statistical significance (one
way ANOVA p = 0.058) (Supplementary Figure 4). Regarding
organ function, renal function was improved in the D1 group
compared to controls, but not the D0.5 animals (Figure 3).
The infusion of salbutamol was associated with a similar
pattern of hemodynamics to those observed in dopexamine
treated animals (Table 1, Figure 1, Supplementary Table 1,
Supplementary Figure 2), and there was also no improvement
in indices of tissue perfusion (Supplementary Figure 3).
Compared to controls, salbutamol significantly reduced
leucocyte-endothelial adhesion (S: 365 ± 49 mm−2, p < 0.01
vs. control) (Figure 2). Salbutamol also appeared to prevent
arteriolar vasoconstriction, but unlike dopexamine was not
associated with any change in FCD in any layer of the muscularis
[Figure 2 (mid, right), Supplementary Figure 4] and had no
effect on organ injury (Figure 3).
DISCUSSION
The principal findings of this experiment were that in a
rodent model of laparotomy and endotoxemia, clinically relevant
doses of dopexamine were associated with decreased leucocyte-
endothelial adhesion and reduced arteriolar constriction in
the intestinal microvasculature. However, with the exception
of an increase in heart rate, dopexamine infusion was not
associated with any systemic cardiovascular effects and in
particular, relative cardiac index was not improved. In the
higher dose dopexamine group an amelioration of renal
dysfunction as assessed by plasma creatinine was observed.
Almost all these findings were replicated by the β2-adrenoceptor
agonist salbutamol though salbutamol failed to improve renal
function (28).
This study provides evidence that dopexamine modulates
the inflammatory response by reducing leucocyte-endothelial
adhesion. We have previously demonstrated that in addition to
reducing the pro-inflammatory cytokine response, dopexamine
may also reduce the expression of leucocyte surface integrins
following endotoxemia. We have also previously demonstrated
a reduction in neutrophil infiltration in the lung of dopexamine
treated endotoxaemic rats (28). It is possible that these
observations are linked, such that during endotoxemia, a
dopexamine mediated reduction in surface integrin expression
results in reduced leucocyte-endothelial adhesion and
consequential neutrophil transmigration into the tissues.
Although this experiment does not elucidate the cellular events
that result in reduced leucocyte-endothelial adhesion, the
similar effects of salbutamol suggest a β2-adrenoceptor mediated
mechanism. In this regard it has been shown that β2- and non-
β2-adrenoceptor mediated elevations of cAMP reduce leucocyte
adhesion (31, 32), whilst tonic activity of Protein Kinase A
prevents β2-integrin activation (33). Other factors including, but
not limited to, an amelioration of pro-inflammatory cytokines or
drug effects on vascular endothelium may be of equal or greater
relevance to these observed changes. Furthermore, the relevance
of reduced leucocyte-endothelial adhesion to the effect of
dopexamine on organ function is also unclear because although
salbutamol reduced leucocyte adhesion in post-capillary venules
it did not ameliorate renal injury.
The reduction in arteriolar vasoconstriction by dopexamine
is consistent with the preservation of arteriolar diameters in
villus arterioles and hepatic sinusoids observed in previous
endotoxemia studies with dopexamine. In those studies,
dopexamine treated endotoxaemic animals had an associated
preservation of total organ and microvascular blood flow
compared to untreated groups (23, 26). However, in our previous
study we observed a reduction in ileal red cell flux during
endotoxemia (28). Assuming the same effect occurred in this
study, then the similar muscularis FCD in control and sham
animals suggests that any perfusion defect (assessed by FCD)
must occur in the mucosa, as has been shown in other studies
using intravital microscopy (34). The non-significant trend to
reduction in longitudinal FCD in dopexamine treated animals
may then indicate a dopexamine mediated re-distribution of
blood from the outer layer of the ileum to the hypoxia prone
mucosa. In this regard it is interesting to note that although
salbutamol and dopexamine had similar effects on arteriolar
diameters, salbutamol did not show any tendency to produce this
effect on longitudinal layer FCD, did not improve renal function
and showed no tendency to a reduced plasma lactate either. These
differences, despite the similarity of effects otherwise, are notable
and warrant further study.
Previous clinical studies in major surgery including those
by our own group have emphasized the role of cardiovascular
optimisation in enhancing tissue oxygen delivery to reduce peri-
operative morbidity (7, 8). Early studies drove clinicians to
suggest this approach was beneficial as it reduced potentially
harmful tissue ischaemia (35). The importance of maintaining
tissue perfusion is still supported by modern studies from peri-
operative medicine where MAP is clamped at higher levels
and shown to reduce the incidence of post-operative morbidity
(36). This may also relate to improvements in microvascular
perfusion (37). However, we previously showed in surgical
patients kept to a narrow MAP range that peri-operative stroke-
volume guided fluid management protocols with continuous 0.5
µg kg−1 min−1 dopexamine infusion produced improvements in
tissue oxygenation but without beneficial effects on markers of
systemic inflammation or organ dysfunction (8). We also showed
in a rodent model that dopexamine 1–2 µg kg−1 min−1 brings
about potent immunomodulatory effects that are associated
with improved organ function despite MAP and microvascular
flow being similar to controls (28). This suggests that under
surgical conditions therapeutic benefit is achievable through
modulation of the host response to tissue injury and that further
increases in tissue oxygenation or blood flow when perfusion
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is already guaranteed are redundant. In support of this, an
analysis of surgical trials shows that patients with higher levels
of baseline systemic inflammation are more likely to develop
surgical complications (38). Similarly patients with impaired pre-
operative microvascular function (who are known to have higher
levels of inflammatory markers) are also more likely to suffer
later complications (37, 39). Considering that previous studies
have shown that surgical stress is associated with an upregulation
of chemokines in the peritoneum and lungs, modulation of the
host response to surgery becomes a potential explanation for
the beneficial effects of dopexamine (40). However, the failure
of salbutamol to improve renal function while producing a very
similar spectrum of immune effects to dopexamine suggests that
the mechanisms of renal protection with dopexamine are not
necessarily only related to β2-adrenoceptor mediated effects on
leucocyte-endothelial adhesion.
Differential abilities of dopexamine and salbutamol to increase
cellular cAMP may explain divergent effects on renal function
(41). This might be the case if dopaminergic receptor activation
by dopexamine further increased cAMP levels above that
provided by β2-adrenoceptor activation (5). The importance of
increasing cAMP is that regulated cell death that causes tissue
injury in acute kidney injury is inhibited by cAMP mediated-
pathways, as is mitochondrial biogenesis which is required
for enhanced recovery from cell stress (42, 43). On the other
hand β2-adrenoceptor activation has also been shown to alter
systemic metabolism to increase tissue tolerance of injury (44).
Therefore, unexpected differential effects of the drugs at β2-
adrenoceptors or in cAMP generation provide two mechanisms
through which tissue damage can be minimized during the
hours during and after emergency laparotomy and elective major
abdominal surgery. This might also provide some explanation
for the opposite findings in trials of β2-adrenoceptor agonism
in acute respiratory distress syndrome (45). In those trials a
week long infusion of higher doses of salbutamol were used to
try and improve outcomes through a reduction in extravascular
lung water but resulted in increased mortality. On the other
hand in peri-operativemedicine shorter-term infusions of similar
agents are used to try and minimize tissue damage and organ
dysfunction that can result from major surgery—trials in this
setting with dopexamine have not shown any signal to increased
mortality (7).
Several findings of this study are consistent with previous
investigations. The haemodynamic effects of endotoxemia with
or without dopexamine were replicated here and are in
keeping with other studies (20, 28). Findings of intestinal
arteriolar constriction are in keeping with the intense splanchnic
vasoconstriction and rapid reduction of blood flow seen
following endotoxemia and shock in rodents (20, 28, 46).
This study, in keeping with other studies, found arteriolar
constriction could be ameliorated by dopexamine (23). Similar
studies have found an increase in adherent leucocyte numbers
in intestinal or mesenteric post-capillary venules that could be
ameliorated by dopexamine (19, 20). A significant increase in
adherent leucocytes (reduced by dopexamine) and a decrease
in rolling leucocyte numbers in post-capillary venules at two
and a half hours would likely have resulted in leukopenia, as
found in other studies (19–23). However, some findings of the
experiment reported here, such as the failure of endotoxemia to
decrease longitudinal and circular muscularis functional capillary
density are not consistent with previous studies (20). These
inconsistencies are likely to be the result of differences in the
endotoxin serotype, dose, method of administration and fluid
loading conditions of each experiment. Our study also appears
to contradict the findings of Schmidt et al. regarding the role
of β2-adrenoceptor agonism in leucocyte-endothelial adhesion
(19). Importantly, our study design avoided the ablation of both
endogenous and exogenous β2–adrenoceptor agonism that may
account for differences in findings between the two studies.
Our study has several strengths. The use of IVM gave
qualitative and quantitative data that is unobtainable from laser
Doppler flowmetry studies (20). The nature of endotoxemia
was modified, using peptidoglycan, which increases the
generalizability of these findings outside of Gram negative
septicaemia alone. Although the duration and nature of
endotoxemia differed from our previous study, the model
behaved in a similar fashion to our previous study with respect
to hemodynamics, markers of perfusion and resultant organ
dysfunction. With respect to biochemical markers of tissue
perfusion, it is possible that the lack of statistical significance
in the D1 group where lactic acidosis and base deficit were less
severe (as in our previous study) is the result of smaller sample
sizes. If correct, it is notable that salbutamol neither showed any
signal to an amelioration of plasma lactate nor resulted in any
amelioration of renal dysfunction. This could suggest there are
additional important mechanisms of action of reducing organ
injury that dopexamine possesses (as discussed above).
There are also limitations to the study performed. Although
there were many similarities with our previous experiments,
fundamental differences in design mean that it is not possible
to be certain that the models behaved in an identical fashion.
Secondly, although the use of IVM permitted direct visualization
of the intestinal microcirculation, expected differences in FCD
were not seen between shams and controls. This may have
related to the mild severity of the model (note no significant
hepatic dysfunction was observed in any group), to visualizing
the intestinal microcirculation too early in the course of the
experiment or even to the volume of fluid administered. In this
regard the inability to observe changes in the microvascular
bed over the entire course of the experiment was a weakness
of this study. Furthermore, although arteriolar diameters and
muscularis FCD were observed, the inability to measure center-
line red cell velocity, mucosal FCD and mucosal inflow arteriolar
diameters prevents a complete picture of the distribution of
intestinal blood flow being made. Although reductions in
leucocyte-endothelial adhesion were observed, it is not possible
to ascertain the relative importance of this phenomenon to the
reduction in organ injury seen in this or previous experiments.
Derivation of the surrogates relative stroke volume and relative
cardiac index from infra-renal blood flow is recognized in the
literature. Nevertheless, it should be noted that cardiac index
may have differed between groups and the effects of different
doses of vasoactive drugs may have led to differing organ blood
flows above the level of measurement, none of which could
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have been detected by an infra-renal flow probe. Regarding
the use of dopexamine and salbutamol, dose equivalence was
based on previous studies in isolated tracheal preparations (30).
Although hemodynamics were similar between D1 and S groups
suggesting the dose selection was probably correct, it is still not
possible to be certain that the effect at the β2-adrenoceptor was
identical for both drugs. This may be compounded by the fact
that salbutamol is a mix of two enantiomers, adding further
complexity to the comparison. In this regard the use of a selective
β2-adrenoceptor antagonist to further disentangle the role of this
drug effects will be useful in future studies. Finally, although
the use of peptidoglycan increases the generalizability of these
findings outside of Gram negative septicaemia, the choice of an
endotoxin based model may still be criticized for lack of a true
clinical correlate.
In summary, we present experimental evidence confirming
that clinically relevant doses of dopexamine reduce leucocyte-
endothelial adhesion in the intestinal microvasculature and
are associated with improved renal function at clinically
relevant doses. As a consequence of our experiments some
avenues warrant further research. The relationship between β2-
adrenoceptor signaling and downstream effects on leucocyte
CD11b expression, tissue tolerance mechanisms and inhibition
of regulated cell death deserve further attention. The effect of
dopexamine on microvascular recruitment and its relationship
to cardiac index under differing fluid regimes and also the
effect of dopexamine on the distribution of microvascular blood
flows are two areas that also warrant further study given the
disparity seen in results of our studies and others (8, 20, 23).
Although peri-operative dopexamine use has been shown to be
safe in randomized controlled trials and a Bayesian analysis of
the OPTIMIZE trial suggested a high probability of superiority
of treatment efficacy, a new randomized controlled trial
of peri-operative optimisation using β2-adrenoceptor agonists
including dopexamine is underway and will inform clinicians
definitively regarding the role of peri-operative dopexamine and
haemodynamic optimisation (7, 47, 48).
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